Anyone considering GLP-1 treatment should plan dose increases during recovery weeks, test all race nutrition during training while on the drug, and monitor training quality alongside the scale
Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network (2022) Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program, Diabetes Care (2022) What causes obesity & overweight?, Eunice Kennedy Shriver National Institute of Child Health and Human Development (2021) Compounding and the FDA: Questions and Answers, Food and Drug Administration (2024) Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes, Reviews in Endocrine and Metabolic Disorders (2022) FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) Thinking of using a compounding pharmacy
G., Ganguly, K., Chaudhuri, K., & Chakrabarty, A
It is most often seen during the early stages of treatment or after dose increases, which is why gradual titration is a central part of the dosing strategy used in clinical studies
